Facioscapulohumeral Muscular Dystrophy As a Model for Epigenetic Regulation and Disease

Antioxidants and Redox Signaling

Volumn 22, Issue 16, 2015, Pages 1463-1482

  Himeda, Charis L ^a   Jones, Takako I ^a   Jones, Peter L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMEODOMAIN PROTEIN; PROTEIN DUX4; REGULATOR PROTEIN; STRUCTURAL MAINTENANCE OF CHROMOSOMES HINGE DOMAIN PROTEIN 1; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALLELE; ARTICLE; CHROMATIN; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DNA METHYLATION; ENVIRONMENTAL FACTOR; EPIGENETICS; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL;

EID: 84929174033     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6090     Document Type: Article

References (181)

1. Allo M, Buggiano V, Fededa JP, Petrillo E, Schor I, de la Mata M, Agirre E, Plass M, Eyras E, Elela SA, Klinck R, Chabot B, and Kornblihtt AR. Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol 16: 717-724, 2009.
2. Ansseau E, Laoudj-Chenivesse D, Marcowycz A, Tassin A, Vanderplanck C, Sauvage S, Barro M, Mahieu I, Leroy A, Leclercq I, Mainfroid V, Figlewicz D, Mouly V, Butler-Browne G, Belayew A, and Coppee F. DUX4c is upregulated in FSHD. It induces the MYF5 protein and human myoblast proliferation. PLoS One 4: e7482, 2009.
3. Arashiro P, Eisenberg I, Kho AT, Cerqueira AM, Canovas M, Silva HC, Pavanello RC, Verjovski-Almeida S, Kunkel LM, and Zatz M. Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci U S A 106: 6220-6225, 2009.
4. Ashe A, Morgan DK, Whitelaw NC, Bruxner TJ, Vickaryous NK, Cox LL, Butterfield NC, Wicking C, Blewitt ME, Wilkins SJ, Anderson GJ, Cox TC, and Whitelaw E. A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development. Genome Biol 9: R182, 2008.
5. Bakker E, Wijmenga C, Vossen RH, Padberg GW, Hewitt J, van der Wielen M, Rasmussen K, and Frants RR. The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve 2: S39-S44, 1995.
6. Balog J, Thijssen PE, de Greef JC, Shah B, van Engelen BG, Yokomori K, Tapscott SJ, Tawil R, and van der Maarel SM. Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD. Epigenetics 7: 1-6, 2012.
7. Baur JA, Zou Y, Shay JW, and Wright WE. Telomere position effect in human cells. Science 292: 2075-2077, 2001.
8. Benchaouir R and Goyenvalle A. Splicing modulation mediated by small nuclear RNAs as therapeutic approaches for muscular dystrophies. Curr Gene Ther 12: 179-191, 2012.
9. Bengtsson U, Altherr MR, Wasmuth JJ, and Winokur ST. High resolution fluorescence in situ hybridization to linearly extended DNA visually maps a tandem repeat associated with facioscapulohumeral muscular dystrophy immediately adjacent to the telomere of 4q. Hum Mol Genet 3: 1801-1805, 1994.
10. Berdasco M and Esteller M. Genetic syndromes caused by mutations in epigenetic genes. Hum Genet 132: 359-383, 2013.
11. Bernstein BE, Meissner A, and Lander ES. The mammalian epigenome. Cell 128: 669-681, 2007.
12. Bickmore WA and van der Maarel SM. Perturbations of chromatin structure in human genetic disease: recent advances. Hum Mol Genet 12 Spec No 2: R207-R213, 2003.
13. Blewitt ME, Gendrel AV, Pang Z, Sparrow DB, Whitelaw N, Craig JM, Apedaile A, Hilton DJ, Dunwoodie SL, Brockdorff N, Kay GF, and Whitelaw E. SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation. Nat Genet 40: 663-669, 2008.
14. Blewitt ME, Vickaryous NK, Hemley SJ, Ashe A, Bruxner TJ, Preis JI, Arkell R, and Whitelaw E. An N-ethyl-N-nitrosourea screen for genes involved in variegation in the mouse. Proc Natl Acad Sci U S A 102: 7629-7634, 2005.
15. Block GJ, Narayanan D, Amell AM, Petek LM, Davidson KC, Bird TD, Tawil R, Moon RT, and Miller DG. Wnt/beta-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Hum Mol Genet 22: 4661-4672, 2013.
16. Block GJ, Petek LM, Narayanan D, Amell AM, Moore JM, Rabaia NA, Tyler A, van der Maarel SM, Tawil R, Filippova GN, and Miller DG. Asymmetric bidirectional transcription from the FSHD-causing D4Z4 array modulates DUX4 production. PLoS One 7: e35532, 2012.
17. Bodega B, Ramirez GD, Grasser F, Cheli S, Brunelli S, Mora M, Meneveri R, Marozzi A, Mueller S, Battaglioli E, and Ginelli E. Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biol 7: 41, 2009.
18. Bosnakovski D, Choi SH, Strasser JM, Toso EA, Walters MA, and Kyba M. High-throughput screening identifies inhibitors of DUX4-induced myoblast toxicity. Skelet Muscle 4: 4, 2014.
19. Bosnakovski D, Daughters RS, Xu Z, Slack JM, and Kyba M. Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS One 4: e7003, 2009.
20. Bosnakovski D, Xu Z, Gang EJ, Galindo CL, Liu M, Simsek T, Garner HR, Agha-Mohammadi S, Tassin A, Coppee F, Belayew A, Perlingeiro RR, and Kyba M. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J 27: 2766-2779, 2008.
21. Bourque G, Leong B, Vega VB, Chen X, Lee YL, Srinivasan KG, Chew JL, Ruan Y, Wei CL, Ng HH, and Liu ET. Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res 18: 1752-1762, 2008.
22. Brook MH. A Clinician's View of Neuromuscular Diseases. Baltimore, MD: Williams and Wilkins, 1977.
23. Broucqsault N, Morere J, Gaillard MC, Dumonceaux J, Torrents J, Salort-Campana E, Maues de Paula A, Bartoli M, Fernandez C, Chesnais AL, Ferreboeuf M, Sarda L, Dufour H, Desnuelle C, Attarian S, Levy N, N'Guyen K, Magdinier F, and Roche S. Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy. Hum Mol Genet 22: 4206-4214, 2013.
24. Brouwer OF, Padberg GW, Wijmenga C, and Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 51: 387-394, 1994.
25. Buck-Koehntop BA and Defossez PA. On how mammalian transcription factors recognize methylated DNA. Epigenetics 8: 131-137, 2013.
26. Cabianca DS, Casa V, Bodega B, Xynos A, Ginelli E, Tanaka Y, and Gabellini D. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell 149: 819-831, 2012.
27. Caruso N, Herberth B, Bartoli M, Puppo F, Dumonceaux J, Zimmermann A, Denadai S, Lebosse M, Roche S, Geng L, Magdinier F, Attarian S, Bernard R, Maina F, Levy N, and Helmbacher F. Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy. PLoS Genet 9: e1003550, 2013.
28. Casa V and Gabellini D. A repetitive elements perspective in polycomb epigenetics. Front Genet 3: 199, 2012.
29. Chadwick BP. DXZ4 chromatin adopts an opposing conformation to that of the surrounding chromosome and acquires a novel inactive X-specific role involving CTCF and antisense transcripts. Genome Res 18: 1259-1269, 2008.
30. Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK, Nishino I, Lin CW, Shih HH, Huang CC, Liang WC, Wang WF, and Jong YJ. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 23: 298-305, 2013.
31. Clapp J, Mitchell LM, Bolland DJ, Fantes J, Corcoran AE, Scotting PJ, Armour JA, and Hewitt JE. Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am J Hum Genet 81: 264-279, 2007.
32. Consortium EP, Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, and Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74, 2012.
33. Creasey KM, Zhai J, Borges F, Van Ex F, Regulski M, Meyers BC, and Martienssen RA. miRNAs trigger widespread epigenetically activated siRNAs from transposons in Arabidopsis. Nature 508: 411-415, 2014.
34. D'Urso A and Brickner JH. Mechanisms of epigenetic memory. Trends Genet 30: 230-236, 2014.
35. Dandapat A, Bosnakovski D, Hartweck LM, Arpke RW, Baltgalvis KA, Vang D, Baik J, Darabi R, Perlingeiro RC, Hamra FK, Gupta K, Lowe DA, and Kyba M. Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene. Cell Rep 8: 1484-1496, 2014.
36. Daxinger L, Harten SK, Oey H, Epp T, Isbel L, Huang E, Whitelaw N, Apedaile A, Sorolla A, Yong J, Bharti V, Sutton J, Ashe A, Pang Z, Wallace N, Gerhardt DJ, Blewitt ME, Jeddeloh JA, and Whitelaw E. An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse. Genome Biol 14: R96, 2013.
37. Daxinger L, Oey H, Apedaile A, Sutton J, Ashe A, and Whitelaw E. A forward genetic screen identifies eukaryotic translation initiation factor 3, subunit H (eIF3h), as an enhancer of variegation in the mouse. G3 (Bethesda) 2: 1393-1396, 2012.
38. de Greef JC, Frants RR, and van der Maarel SM. Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res 647: 94-102, 2008.
39. de Greef JC, Lemmers RJ, Camano P, Day JW, Sacconi S, Dunand M, van Engelen BG, Kiuru-Enari S, Padberg GW, Rosa AL, Desnuelle C, Spuler S, Tarnopolsky M, Venance SL, Frants RR, van der Maarel SM, and Tawil R. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 75: 1548-1554, 2010.
40. de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, Frants RR, Tawil R, and van der Maarel SM. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 30: 1449-1459, 2009.
41. Deidda G, Cacurri S, Grisanti P, Vigneti E, Piazzo N, and Felicetti L. Physical mapping evidence for a duplicated region on chromosome 10qter showing high homology with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter. Eur J Hum Genet 3: 155-167, 1995.
42. Dejardin J, Rappailles A, Cuvier O, Grimaud C, Decoville M, Locker D, and Cavalli G. Recruitment of Drosophila polycomb group proteins to chromatin by DSP1. Nature 434: 533-538, 2005.
43. Dixit M, Ansseau E, Tassin A, Winokur S, Shi R, Qian H, Sauvage S, Matteotti C, van Acker AM, Leo O, Figlewicz D, Barro M, Laoudj-Chenivesse D, Belayew A, Coppee F, and Chen YW. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A 104: 18157-18162, 2007.
44. Dolinoy DC, Das R, Weidman JR, and Jirtle RL. Metastable epialleles, imprinting, and the fetal origins of adult diseases. Pediatr Res 61: 30R-37R, 2007.
45. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, Ku M, Durham T, Kellis M, and Bernstein BE. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49, 2011.
46. Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C, Irvine KM, Schroder K, Cloonan N, Steptoe AL, Lassmann T, Waki K, Hornig N, Arakawa T, Takahashi H, Kawai J, Forrest AR, Suzuki H, Hayashizaki Y, Hume DA, Orlando V, Grimmond SM, and Carninci P. The regulated retrotransposon transcriptome of mammalian cells. Nat Genet 41: 563-571, 2009.
47. Feinberg AP and Tycko B. The history of cancer epigenetics. Nat Rev Cancer 4: 143-153, 2004.
48. Ferreboeuf M, Mariot V, Bessieres B, Vasiljevic A, Attie-Bitach T, Collardeau S, Morere J, Roche S, Magdinier F, Robin-Ducellier J, Rameau P, Whalen S, Desnuelle C, Sacconi S, Mouly V, Butler-Browne G, and Dumonceaux J. DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles. Hum Mol Genet 23: 171-181, 2014.
49. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Perez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, and Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
50. Gabellini D, D'Antona G, Moggio M, Prelle A, Zecca C, Adami R, Angeletti B, Ciscato P, Pellegrino MA, Bottinelli R, Green MR, and Tupler R. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439: 973-977, 2006.
51. Gabellini D, Green MR, and Tupler R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110: 339-348, 2002.
52. Gabriels J, Beckers MC, Ding H, De Vriese A, Plaisance S, van der Maarel SM, Padberg GW, Frants RR, Hewitt JE, Collen D, and Belayew A. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236: 25-32, 1999.
53. Gapp K, Woldemichael BT, Bohacek J, and Mansuy IM. Epigenetic regulation in neurodevelopment and neurodegenerative diseases. Neuroscience 264: 99-111, 2014.
54. Gendrel AV, Apedaile A, Coker H, Termanis A, Zvetkova I, Godwin J, Tang YA, Huntley D, Montana G, Taylor S, Giannoulatou E, Heard E, Stancheva I, and Brockdorff N. Smchd1-dependent and -independent pathways determine developmental dynamics of CpG island methylation on the inactive X chromosome. Dev Cell 23: 265-279, 2012.
55. Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, van der Maarel SM, Ruzzo WL, Gentleman RC, Tawil R, and Tapscott SJ. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell 22: 38-51, 2012.
56. Gilbert JR, Stajich JM, Wall S, Carter SC, Qiu H, Vance JM, Stewart CS, Speer MC, Pufky J, Yamaoka LH, Rozear M, Samson F, Fardeau M, Roses AD, and Pericak-Vance MA. Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD). Am J Hum Genet 53: 401-408, 1993.
57. Goto K, Lee JH, Matsuda C, Hirabayashi K, Kojo T, Nakamura A, Mitsunaga Y, Furukawa T, Sahashi K, and Arahata K. DNA rearrangements in Japanese facioscapulohumeral muscular dystrophy patients: clinical correlations. Neuromuscul Disord 5: 201-208, 1995.
58. Goto K, Nishino I, and Hayashi YK. Very low penetrance in 85 Japanese families with facioscapulohumeral muscular dystrophy 1A. J Med Genet 41: e12, 2004.
59. Gregory GD, Vakoc CR, Rozovskaia T, Zheng X, Patel S, Nakamura T, Canaani E, and Blobel GA. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol 27: 8466-8479, 2007.
60. Griggs RC, Tawil R, McDermott M, Forrester J, Figlewicz D, and Weiffenbach B. Monozygotic twins with facioscapulohumeral dystrophy (FSHD): implications for genotype/phenotype correlation. FSH-DY group. Muscle Nerve 2: S50-S55, 1995.
61. Grolimund L, Aeby E, Hamelin R, Armand F, Chiappe D, Moniatte M, and Lingner J. A quantitative telomeric chromatin isolation protocol identifies different telomeric states. Nat Commun 4: 2848, 2013.
62. Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CM, and Gartler SM. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci U S A 96: 14412-14417, 1999.
63. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, and Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405: 486-489, 2000.
64. Harris RA, Nagy-Szakal D, and Kellermayer R. Human metastable epiallele candidates link to common disorders. Epigenetics 8: 157-163, 2013.
65. Hartweck LM, Anderson LJ, Lemmers RJ, Dandapat A, Toso EA, Dalton JC, Tawil R, Day JW, van der Maarel SM, and Kyba M. A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology 80: 392-399, 2013.
66. He F and Todd PK. Epigenetics in nucleotide repeat expansion disorders. Semin Neurol 31: 470-483, 2011.
67. Heard E and Martienssen RA. Transgenerational epigenetic inheritance: myths and mechanisms. Cell 157: 95-109, 2014.
68. Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C, van Deutekom JC, Francis F, Sharpe PT, Hofker M, Frants RR, and Williamson R. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 3: 1287-1295, 1994.
69. Heyn H. A symbiotic liaison between the genetic and epigenetic code. Front Genet 5: 113, 2014.
70. Himeda CL, Debarnot C, Homma S, Beermann ML, Miller JB, Jones PL, and Jones TI. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy associated DUX4 gene. Mol Cell Biol 34: 1942-1955, 2014.
71. Homma S, Chen JC, Rahimov F, Beermann ML, Hanger K, Bibat GM, Wagner KR, Kunkel LM, Emerson CP, Jr., and Miller JB. A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet 20: 404-410, 2012.
72. Illingworth RS and Bird AP. CpG islands - 'a rough guide'. FEBS Lett 583: 1713-1720, 2009.
73. Ivanov AV, Peng H, Yurchenko V, Yap KL, Negorev DG, Schultz DC, Psulkowski E, Fredericks WJ, White DE, Maul GG, Sadofsky MJ, Zhou MM, and Rauscher FJ, 3rd. PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol Cell 28: 823-837, 2007.
74. Jaenisch R and Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33 Suppl: 245-254, 2003.
75. Jiang G, Yang F, van Overveld PG, Vedanarayanan V, van der Maarel S, and Ehrlich M. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q. Hum Mol Genet 12: 2909-2921, 2003.
76. Jirtle RL and Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8: 253-262, 2007.
77. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13: 484-492, 2012.
78. Jones TI, Chen JC, Rahimov F, Homma S, Arashiro P, Beermann ML, King OD, Miller JB, Kunkel LM, Emerson CP, Jr., Wagner KR, and Jones PL. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum Mol Genet 21: 4419-4430, 2012.
79. Jones TI, Debarnot C, Himeda CL, Sun C-YJ, Emerson CP, and Jones PL. Epigenetic variability is a modifier of facioscapulohumeral muscular dystrophy (Abstract). Neuromuscul Disord 23: 825, 2013.
80. Karagianni P, Amazit L, Qin J, and Wong J. ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol 28: 705-717, 2008.
81. Keller C and Buhler M. Chromatin-associated ncRNA activities. Chromosome Res 21: 627-641, 2013.
82. Kim DH, Villeneuve LM, Morris KV, and Rossi JJ. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol 13: 793-797, 2006.
83. Kimura H. Histone modifications for human epigenome analysis. J Hum Genet 58: 439-445, 2013.
84. Kisseljova NP, Dmitriev P, Katargin A, Kim E, Ezerina D, Markozashvili D, Malysheva D, Planche E, Lemmers RJ, van der Maarel SM, Laoudj-Chenivesse D, Lipinski M, and Vassetzky YS. DNA polymorphism and epigenetic marks modulate the affinity of a scaffold/matrix attachment region to the nuclear matrix. Eur J Hum Genet 22: 1117-1123, 2014.
85. Klinge L, Eagle M, Haggerty ID, Roberts CE, Straub V, and Bushby KM. Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord 16: 553-558, 2006.
86. Klooster R, Straasheijm K, Shah B, Sowden J, Frants R, Thornton C, Tawil R, and van der Maarel S. Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet 17: 1615-1624, 2009.
87. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, and Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet 41: 376-381, 2009.
88. Kouzarides T. Chromatin modifications and their function. Cell 128: 693-705, 2007.
89. Kowaljow V, Marcowycz A, Ansseau E, Conde CB, Sauvage S, Matteotti C, Arias C, Corona ED, Nunez NG, Leo O, Wattiez R, Figlewicz D, Laoudj-Chenivesse D, Belayew A, Coppee F, and Rosa AL. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 17: 611-623, 2007.
90. Krom YD, Thijssen PE, Young JM, den Hamer B, Balog J, Yao Z, Maves L, Snider L, Knopp P, Zammit PS, Rijkers T, van Engelen BG, Padberg GW, Frants RR, Tawil R, Tapscott SJ, and van der Maarel SM. Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD. PLoS Genet 9: e1003415, 2013.
91. Law JA and Jacobsen SE. Establishing, maintaining and modifying DNA methylation patterns in plants and animals. Nat Rev Genet 11: 204-220, 2010.
92. Leidenroth A, Clapp J, Mitchell LM, Coneyworth D, Dearden FL, Iannuzzi L, and Hewitt JE. Evolution of DUX gene macrosatellites in placental mammals. Chromosoma 121: 489-497, 2012.
93. Lejeune E and Allshire RC. Common ground: small RNA programming and chromatin modifications. Curr Opin Cell Biol 23: 258-265, 2011.
94. Lemmers RJ, de Kievit P, Sandkuijl L, Padberg GW, van Ommen GJ, Frants RR, and van der Maarel SM. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet 32: 235-236, 2002.
95. Lemmers RJ, Tawil R, Petek LM, Balog J, Block GJ, Santen GW, Amell AM, van der Vliet PJ, Almomani R, Straasheijm KR, Krom YD, Klooster R, Sun Y, den Dunnen JT, Helmer Q, Donlin-Smith CM, Padberg GW, van Engelen BG, de Greef JC, Aartsma-Rus AM, Frants RR, de Visser M, Desnuelle C, Sacconi S, Filippova GN, Bakker B, Bamshad MJ, Tapscott SJ, Miller DG, and van der Maarel SM. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 44: 1370-1374, 2012.
96. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, Tawil R, Frants RR, and van der Maarel SM. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329: 1650-1653, 2010.
97. Lemmers RJ, van der Vliet PJ, van der Gaag KJ, Zuniga S, Frants RR, de Knijff P, and van der Maarel SM. Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete interchromosomal sequence transfers in human evolution. Am J Hum Genet 86: 364-377, 2010.
98. Lemmers RJ, Wohlgemuth M, Frants RR, Padberg GW, Morava E, and van der Maarel SM. Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy. Am J Hum Genet 75: 1124-1130, 2004.
99. Lemmers RJ, Wohlgemuth M, van der Gaag KJ, van der Vliet PJ, van Teijlingen CM, de Knijff P, Padberg GW, Frants RR, and van der Maarel SM. Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 81: 884-894, 2007.
100. Lemmers RJL, de Kievit P, van Geel M, van der Wielen MJ, Bakker E, Padberg GW, Frants RR, and van der Maarel SM. Complete allele information in the diagnosis of facioscapulohumeral muscular dystrophy by triple DNA analysis. Ann Neurol 50: 816-819, 2001.
101. Lorkovic ZJ, Naumann U, Matzke AJ, and Matzke M. Involvement of a GHKL ATPase in RNA-directed DNA methylation in Arabidopsis thaliana. Curr Biol 22: 933-938, 2012.
102. Luco RF, Allo M, Schor IE, Kornblihtt AR, and Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell 144: 16-26, 2011.
103. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, and Misteli T. Regulation of alternative splicing by histone modifications. Science 327: 996-1000, 2010.
104. Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, Harper PS, and Upadhyaya M. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 4: 951-958, 1995.
105. Lyle R, Wright TJ, Clark LN, and Hewitt JE. The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics 28: 389-397, 1995.
106. Maison C, Bailly D, Roche D, Montes de Oca R, Probst AV, Vassias I, Dingli F, Lombard B, Loew D, Quivy JP, and Almouzni G. SUMOylation promotes de novo targeting of HP1alpha to pericentric heterochromatin. Nat Genet 43: 220-227, 2011.
107. Maraldi NM, Capanni C, Cenni V, Fini M, and Lattanzi G. Laminopathies and lamin-associated signaling pathways. J Cell Biochem 112: 979-992, 2011.
108. Masny PS, Bengtsson U, Chung SA, Martin JH, van Engelen B, van der Maarel SM, and Winokur ST. Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease? Hum Mol Genet 13: 1857-1871, 2004.
109. Maunakea AK, Chepelev I, Cui K, and Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 23: 1256-1269, 2013.
110. Merkenschlager M and Odom DT. CTCF and cohesin: linking gene regulatory elements with their targets. Cell 152: 1285-1297, 2013.
111. Mitsuhashi H, Mitsuhashi S, Lynn-Jones T, Kawahara G, and Kunkel LM. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy. Hum Mol Genet 22: 568-577, 2013.
112. Morgan DK and Whitelaw E. The case for transgenerational epigenetic inheritance in humans. Mamm Genome 19: 394-397, 2008.
113. Mould AW, Pang Z, Pakusch M, Tonks ID, Stark M, Carrie D, Mukhopadhyay P, Seidel A, Ellis JJ, Deakin J, Wakefield MJ, Krause L, Blewitt ME, and Kay GF. Smchd1 regulates a subset of autosomal genes subject to monoallelic expression in addition to being critical for X inactivation. Epigenetics Chromatin 6: 19, 2013.
114. Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M, Xue S, Duan S, Allali-Hassani A, Zuo X, Wang YX, Bronner C, Chedin F, Arrowsmith CH, and Dhe-Paganon S. Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. J Biol Chem 286: 24300-24311, 2011.
115. Orphanet. Prevalence of rare diseases: bibliographic data in Orphanet report series: rare diseases collection. In: Orphanet Report Series: Rare Diseases Collection. Inserm, 2011. http:www.orpha.net/orphacom/cahiers/docs/GB/Prevalence-of-rare-diseases-by-alphabetical-list.pdf
116. Ottaviani A, Rival-Gervier S, Boussouar A, Foerster AM, Rondier D, Sacconi S, Desnuelle C, Gilson E, and Magdinier F. The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulohumeral dystrophy. PLoS Genet 5: e1000394, 2009.
117. Padberg GW. Facioscapulohumeral Disease [thesis]. Leiden, The Netherlands: Leiden University, 1982.
118. Pal-Bhadra M, Leibovitch BA, Gandhi SG, Chikka MR, Bhadra U, Birchler JA, and Elgin SC. Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 303: 669-672, 2004.
119. Petrov A, Allinne J, Pirozhkova I, Laoudj D, Lipinski M, and Vassetzky YS. A nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: implications for the facio-scapulo-humeral dystrophy. Genome Res 18: 39-45, 2008.
120. Petrov A, Pirozhkova I, Carnac G, Laoudj D, Lipinski M, and Vassetzky YS. Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy patients versus normal human myoblasts. Proc Natl Acad Sci U S A 103: 6982-6987, 2006.
121. Pirozhkova I, Petrov A, Dmitriev P, Laoudj D, Lipinski M, and Vassetzky Y. A functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. PLoS One 3: e3389, 2008.
122. Probst AV, Okamoto I, Casanova M, El Marjou F, Le Baccon P, and Almouzni G. A strand-specific burst in transcription of pericentric satellites is required for chromocenter formation and early mouse development. Dev Cell 19: 625-638, 2010.
123. Rahimov F, King OD, Leung DG, Bibat GM, Emerson CP, Jr., Kunkel LM, and Wagner KR. Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers. Proc Natl Acad Sci U S A 109: 16234-16239, 2012.
124. Rakyan VK, Blewitt ME, Druker R, Preis JI, and Whitelaw E. Metastable epialleles in mammals. Trends Genet 18: 348-351, 2002.
125. Reed PW, Corse AM, Porter NC, Flanigan KM, and Bloch RJ. Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy. Exp Neurol 205: 583-586, 2007.
126. Resendiz M, Chen Y, Ozturk NC, and Zhou FC. Epigenetic medicine and fetal alcohol spectrum disorders. Epigenomics 5: 73-86, 2013.
127. Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, Piazzo N, Servidei S, Vigneti E, Pasceri V, Silvestri G, Mirabella M, Mangiola F, Tonali P, and Felicetti L. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 45: 751-757, 1999.
128. Ricci G, Scionti I, Sera F, Govi M, D'Amico R, Frambolli I, Mele F, Filosto M, Vercelli L, Ruggiero L, Berardinelli A, Angelini C, Antonini G, Bucci E, Cao M, Daolio J, Di Muzio A, Di Leo R, Galluzzi G, Iannaccone E, Maggi L, Maruotti V, Moggio M, Mongini T, Morandi L, Nikolic A, Pastorello E, Ricci E, Rodolico C, Santoro L, Servida M, Siciliano G, Tomelleri G, and Tupler R. Large scale genotype-phenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain 136: 3408-3417, 2013.
129. Rijkers T, Deidda G, van Koningsbruggen S, van Geel M, Lemmers RJ, van Deutekom JC, Figlewicz D, Hewitt JE, Padberg GW, Frants RR, and van der Maarel SM. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. J Med Genet 41: 826-836, 2004.
130. Rossi M, Ricci E, Colantoni L, Galluzzi G, Frusciante R, Tonali PA, and Felicetti L. The facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure. BMC Med Genet 8: 8, 2007.
131. Rothbart SB, Krajewski K, Nady N, Tempel W, Xue S, Badeaux AI, Barsyte-Lovejoy D, Martinez JY, Bedford MT, Fuchs SM, Arrowsmith CH, and Strahl BD. Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat Struct Mol Biol 19: 1155-1160, 2012.
132. Rothbart SB and Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta 1839: 627-643, 2014.
133. Sabin LR, Delas MJ, and Hannon GJ. Dogma derailed: the many influences of RNA on the genome. Mol Cell 49: 783-794, 2013.
134. Sacconi S, Lemmers RJ, Balog J, van der Vliet PJ, Lahaut P, van Nieuwenhuizen MP, Straasheijm KR, Debipersad RD, Vos-Versteeg M, Salviati L, Casarin A, Pegoraro E, Tawil R, Bakker E, Tapscott SJ, Desnuelle C, and van der Maarel SM. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 93: 744-751, 2013.
135. Saint-Andre V, Batsche E, Rachez C, and Muchardt C. Histone H3 lysine 9 trimethylation and HP1gamma favor inclusion of alternative exons. Nat Struct Mol Biol 18: 337-344, 2011.
136. Sakellariou P, Kekou K, Fryssira H, Sofocleous C, Manta P, Panousopoulou A, Gounaris K, and Kanavakis E. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. Neuromuscul Disord 22: 339-349, 2012.
137. Sarda S and Hannenhalli S. Next-generation sequencing and epigenomics research: a hammer in search of nails. Genomics Inform 12: 2-11, 2014.
138. Schaap M, Lemmers RJ, Maassen R, van der Vliet PJ, Hoogerheide LF, van Dijk HK, Basturk N, de Knijff P, and van der Maarel SM. Genome-wide analysis of macrosatellite repeat copy number variation in worldwide populations: evidence for differences and commonalities in size distributions and size restrictions. BMC Genomics 14: 143, 2013.
139. Schwartz YB and Pirrotta V. A new world of polycombs: unexpected partnerships and emerging functions. Nat Rev Genet 14: 853-864, 2013.
140. Scionti I, Fabbri G, Fiorillo C, Ricci G, Greco F, D'Amico R, Termanini A, Vercelli L, Tomelleri G, Cao M, Santoro L, Percesepe A, and Tupler R. Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling. J Med Genet 49: 171-178, 2012.
141. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R, and Oberdoerffer S. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 479: 74-79, 2011.
142. Snider L, Asawachaicharn A, Tyler AE, Geng LN, Petek LM, Maves L, Miller DG, Lemmers RJ, Winokur ST, Tawil R, van der Maarel SM, Filippova GN, and Tapscott SJ. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 18: 2414-2430, 2009.
143. Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, and Miller DG. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 6: e1001181, 2010.
144. Stadler G, Rahimov F, King OD, Chen JC, Robin JD, Wagner KR, Shay JW, Emerson CP, Jr., and Wright WE. Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. Nat Struct Mol Biol 20: 671-678, 2013.
145. Stout K, van der Maarel S, Frants RR, Padberg GW, Ropers HH, and Haaf T. Somatic pairing between subtelomeric chromosome regions: implications for human genetic disease? Chromosome Res 7: 323-329, 1999.
146. Sumanasekera C, Watt DS, and Stamm S. Substances that can change alternative splice-site selection. Biochem Soc Trans 36: 483-490, 2008.
147. Tanaka Y, Katagiri Z, Kawahashi K, Kioussis D, and Kitajima S. Trithorax-group protein ASH1 methylates histone H3 lysine 36. Gene 397: 161-168, 2007.
148. Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, King W, Weiffenbach B, and Figlewicz D. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY group. Ann Neurol 39: 744-748, 1996.
149. Tawil R, Storvick D, Feasby TE, Weiffenbach B, and Griggs RC. Extreme variability of expression in monozygotic twins with FSH muscular dystrophy. Neurology 43: 345-348, 1993.
150. Tawil R and Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 34: 1-15, 2006.
151. Tawil R, van der Maarel SM, and Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 4: 12, 2014.
152. Tirard M, Hsiao HH, Nikolov M, Urlaub H, Melchior F, and Brose N. In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice. Proc Natl Acad Sci U S A 109: 21122-21127, 2012.
153. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, and Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 14: 33-38, 2004.
154. Tupler R, Barbierato L, Memmi M, Sewry CA, De Grandis D, Maraschio P, Tiepolo L, and Ferlini A. Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression. J Med Genet 35: 778-783, 1998.
155. Tyekucheva S, Yolken RH, McCombie WR, Parla J, Kramer M, Wheelan SJ, and Sabunciyan S. Establishing the baseline level of repetitive element expression in the human cortex. BMC Genomics 12: 495, 2011.
156. van der Maarel SM, Frants RR, and Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta 1772: 186-194, 2007.
157. van der Maarel SM, Miller DG, Tawil R, Filippova GN, and Tapscott SJ. Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation. Curr Opin Neurol 25: 614-620, 2012.
158. van Deutekom JC, Bakker E, Lemmers RJ, van der Wielen MJ, Bik E, Hofker MH, Padberg GW, and Frants RR. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet 5: 1997-2003, 1996.
159. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, van Ommen GJ, Hofker MH, and Frants RR. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 2: 2037-2042, 1993.
160. van Overveld PG, Enthoven L, Ricci E, Rossi M, Felicetti L, Jeanpierre M, Winokur ST, Frants RR, Padberg GW, and van der Maarel SM. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 58: 569-576, 2005.
161. van Overveld PG, Lemmers RJ, Sandkuijl LA, Enthoven L, Winokur ST, Bakels F, Padberg GW, van Ommen GJ, Frants RR, and van der Maarel SM. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 35: 315-317, 2003.
162. Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivesse D, Wilton SD, Coppee F, and Belayew A. The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 6: e26820, 2011.
163. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, and Martienssen RA. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297: 1833-1837, 2002.
164. Wallace LM, Garwick SE, Mei W, Belayew A, Coppee F, Ladner KJ, Guttridge D, Yang J, and Harper SQ. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 69: 540-552, 2011.
165. Wallace LM, Liu J, Domire JS, Garwick-Coppens SE, Guckes SM, Mendell JR, Flanigan KM, and Harper SQ. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 20: 1417-1423, 2012.
166. Waterland RA and Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23: 5293-5300, 2003.
167. Wijmenga C, Frants RR, Brouwer OF, Moerer P, Weber JL, and Padberg GW. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 336: 651-653, 1990.
168. Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, Gruter AM, Hofker MH, Moerer P, Williamson R, van Ommen GJ, Padberg GW, and Frants RR. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 2: 26-30, 1992.
169. Winokur ST, Bengtsson U, Feddersen J, Mathews KD, Weiffenbach B, Bailey H, Markovich RP, Murray JC, Wasmuth JJ, Altherr MR, et al. The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease. Chromosome Res 2: 225-234, 1994.
170. Wohlgemuth M, Lemmers RJ, van der Kooi EL, van der Wielen MJ, van Overveld PG, Dauwerse H, Bakker E, Frants RR, Padberg GW, and van der Maarel SM. Possible phenotypic dosage effect in patients compound heterozygous for FSHD-sized 4q35 alleles. Neurology 61: 909-913, 2003.
171. Wuebbles RD, Long SW, Hanel ML, and Jones PL. Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol 3: 386-400, 2010.
172. Xi Z, Zinman L, Moreno D, Schymick J, Liang Y, Sato C, Zheng Y, Ghani M, Dib S, Keith J, Robertson J, and Rogaeva E. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet 92: 981-989, 2013.
173. Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, and Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402: 187-191, 1999.
174. Yang F, Shao C, Vedanarayanan V, and Ehrlich M. Cytogenetic and immuno-FISH analysis of the 4q subtelomeric region, which is associated with facioscapulohumeral muscular dystrophy. Chromosoma 112: 350-359, 2004.
175. Young JM, Whiddon JL, Yao Z, Kasinathan B, Snider L, Geng LN, Balog J, Tawil R, van der Maarel SM, and Tapscott SJ. DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis. PLoS Genet 9: e1003947, 2013.
176. Yuan W, Xu M, Huang C, Liu N, Chen S, and Zhu B. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 286: 7983-7989, 2011.
177. Yusufzai TM and Felsenfeld G. The 5′-HS4 chicken beta-globin insulator is a CTCF-dependent nuclear matrix-associated element. Proc Natl Acad Sci U S A 101: 8620-8624, 2004.
178. Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC, and Passos-Bueno MR. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet 77: 155-161, 1998.
179. Zeng W, Chen YY, Newkirk DA, Wu B, Balog J, Kong X, Ball AR, Jr., Zanotti S, Tawil R, Hashimoto N, Mortazavi A, van der Maarel SM, and Yokomori K. Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are distinct from non-4q/10q D4Z4 homologs. Hum Mutat 35: 998-1010, 2014.
180. Zeng W, de Greef JC, Chen YY, Chien R, Kong X, Gregson HC, Winokur ST, Pyle A, Robertson KD, Schmiesing JA, Kimonis VE, Balog J, Frants RR, Ball AR, Jr., Lock LF, Donovan PJ, van der Maarel SM, and Yokomori K. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 5: e1000559, 2009.
181. Zhang Y, Forner J, Fournet S, and Jeanpierre M. Improved characterization of FSHD mutations. Ann Genetique 44: 105-110, 2001.